EGFR and non-small cell lung carcinoma: However, EGFR-TKI resistance is the greatest challenge for NSCLC patients with EGFR mutation in choosing TKI therapy, with approximately 10% of these patients showing primary TKI resistance, while 70% of them eventually develop acquired resistance to EGFR–TKIs [9].